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Article abstract— Central neurogenic hyperventilation (CNH), for which there is no effective therapy, can eventually result in 
respiratory fatigue and death. This report describes a patient with CNH due to a brainstem anaplastic astrocytoma who also 
exhibited disturbances of sleep and ocular motor function. The CNH responded clinically to morphine sulfate and methadone. 
Analysis of ventilatory response to C02 before and after morphine demonstrated a depression of ventilatory response (49 to 53% 
of baseline) and occlusion pressure response (35 to 50% of baseline) to C02, with a requirement for high doses of naloxone (10 mg 
IV) to reverse the effect. Polysomnography revealed sustained hyperventilation, elevated 0 2 saturation, and low end-tidal C02 
throughout all stages of non-rapid eye movement (NREM) sleep, and absence of rapid eye movement (REM) sleep. Ocular motor 
evaluation disclosed absence of horizontal and reflexive saccades with compensatory head thrusts. Correlation of the clinical and 
physiologic data with the MRI abnormalities suggested that the lesion responsible for CNH in this patient might reside in the 
medial tegmental parapontine reticular formation. Since recurrent episodes of hyperventilation responded in a sustained fashion 
to IV and oral opiates, this treatment may warrant consideration in other patients with CNH.
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Central neurogenic hyperventilation (CNH) is charac­
terized by sustained tachypnea that persists despite an 
elevated arterial P o2 and pH and a low arterial P co2. By 
definition, CNH occurs in the absence of a respiratory 
stimulant and persists during sleep. Hepatic encepha­
lopathy and brainstem tumors have been associated 
with this condition.1-2 The mechanisms of production of 
CNH are unclear,3 and there is no effective treatment. 
Persistent hyperventilation can eventually produce res­
piratory fatigue and death.1
This report describes the successful treatment of a 
patient with CNH with opiates. Ventilation was as­
sessed quantitatively by documenting the response to 
C 02 before and after administration of IV morphine 
and naloxone. Since this patient manifested disorders 
of extraocular movements and sleep, we also analyzed 
ocular motor function and performed polysomnography 
to search for clues that might lead to a better under­
standing of the pathophysiology of CNH.
Case report. A 32-year-old woman with neurofibromatosis 
had a 3-month history of diplopia, right-hand numbness, 
occipital and neck pain, intermittent twitching of the right 
eyelid and hand, and unsteady gait. Examination revealed 
poor pursuit, with absent horizontal volitional and spon­
taneous saccades but relative sparing of vertical eye move­
ments. Full eye movements were obtained with vestibulo- 
ocular reflexes. She made typical head-thrusting movements
along with blinks to change fixation. After the head thrust 
overshot the intended target, the eyes would fixate and a 
slower movement of the head would allow the eyes to resume 
their normal alignment. These movements were similar to 
those described in congenital ocular motor apraxia.4 Electro­
oculogram (EOG) revealed no volitional horizontal saccades. 
Optokinetic nystagmus was absent in the horizontal plane and 
present in the vertical plane. A decreased right comeal reflex, 
bilateral ptosis, right facial myokymia, truncal and gait ataxia, 
and mild right-sided appendicular ataxia were present. There 
was a mild right hemiparesis, hypertonia, hyperreflexia, and 
hemisensory deficit that equally affected the face, arm, and 
leg. Also noted were a hyperreflexic jaw jerk and bilateral 
Babinski signs. Multiple cafe-au-lait spots and subcutaneous 
nodules were present. MRI showed abnormal signal from the 
upper medulla to the pons, enveloping the 4th ventricle and 
distal aqueduct (figure 1, A and B). Stereotactic biopsy of the 
tumor in the pontine tegmentum revealed an anaplastic astro­
cytoma without necrosis. The patient received dexa- 
methasone, 16 mg/d, and radiotherapy 5,500 cGy to the 
posterior fossa in 30 fractions over 44 days.
Two weeks after a tapered discontinuation of the dexa- 
methasone (3 months after biopsy; 5 weeks after completion of 
radiotherapy), the patient developed tachypnea, vomiting, 
diplopia, gait instability, slurred speech, and recurrent neck 
and head pain. Her husband reported that her tachypnea did 
not diminish during sleep, which he described as fitful. On 
admission, she was alert and oriented, but had a respiratory 
rate of 36 per minute with consistently deep breaths. Heart 
rate was 151 per minute, blood pressure 150/120 mm Hg,
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Figure 1. Localization of the brainstem anaplastic astrocytoma by MRI. Sagittal (A, C, E, and G) and axial (B, D, F, and H) 
views. A through D were proton density images (gadolinium was not ye t available), while E  through H  were T, images with 
gadolinium enhancement. (A and B) Prior to biopsy and therapy. Abnormal signal is present from the upper medulla to the 
pons, enveloping the 4th ventricle and distal aqueduct. (C and D) Scan 3 months later, at the time of initial development of 
CNH. Progressive caudal extension of the abnormal signal into the ventral medulla has occurred. (E and F) Gadolinium 
M RI 10 months after diagnosis, showing enhancement in the ventral rostral medulla, and pontine tegmentum and tectum. 
(G and H) A t 30 months, after chemotherapy and off steroids, showing reduction in enhancing tissue.
temperature 37 °C. Arterial blood gases on room air were Po2 
121 mm Hg, Pco2 7.6 mm Hg, pH 7.65, HC03_ 8.4 mEq/I, and 
base deficit —4.9 mEq/1. Unfortunately, CSF and serum lac­
tate values were not obtained; urine pH was 6.5. An ECG 
showed sinus tachycardia, and chest x-ray was normal. A 
ventilation-perfusion scan was negative for pulmonary em­
boli. There was no histoiy of cyanide or salicylate exposure, 
and the drug screen was negative. The ocular motor paresis 
with compensatory head thrusts persisted; vestibulo-ocular 
reflexes now identified mild bilateral abducens palsies and a 
mild left internuclear ophthalmoplegia. Additional new find­
ings on examination included bilaterally increased tone, in­
creased truncal ataxia, slurred speech, and decreased palatal 
elevation and gag reflex. MRI showed progressive caudal ex­
tension of the abnormal signal into the medulla (figure 1, C and 
D). The patient could not volitionally inhibit the respiratory 
drive for more than 3 seconds. C02 rebreathing augmented the 
patient’s need to breathe and increased the respiratory rate. 
One hundred percent 0 2 did not inhibit respirations despite 
changing the blood gases (Po2 259 mm Hg, Pco2 8.3 mm Hg, 
pH 7.66, HC03 - 9.3 mEq/1, base deficit —4.4 mEq/1). Mid­
azolam, 5 mg IV, resulted in somnolence but no reduction in 
respiratory rate. Morphine sulfate, 5 mg IV over 5 minutes, 
immediately decreased the respiratory rate to 20 per minute 
without mental status depression. The patient was started on 
methadone, 5 mg q8h po, and respiratory rate remained at 20 
to 28 per minute. Methadone, 10 mg q8h, further reduced 
respiratory rate to 18 per minute but caused confusion. After 
control of the respiratory rate was established, tachycardia 
and hypertension were treated with propranolol, 40 mg q6h, 
but within 24 hours, enalapril 10 mg ql2h was required to 
control the hypertension. Dexamethasone, 10 mg q6h, was 
initiated 24 hours after the morphine sulfate. Over the next 5
days on methadone, her arterial blood gases on room air were 
Po2 85 to 93 mm Hg, Pco2 22 to 27 mm Hg, pH 7.52 to 7.60, 
HC03~ 17 to 22 mEq/1, and base deficit —2.4 to +2.4 mEq/1. 
On the 6th day, the methadone was discontinued but only a 
modest tachypnea (15 to 20 per minute) developed.
Chemotherapy was started with procarbazine, lomustine 
(CCNU), and vincristine (PCV) for presumed progression of 
her brainstem tumor. Repeat MRI 3 months later disclosed a 
slight reduction in tumor size (not shown). Over the next 9 
months, during which time she received 5 courses of PCV, 
there were no episodes of symptomatic CNH, although mild 
tachypnea (15 to 20 per minute) persisted. The patient then 
developed severe tachypnea when her dexamethasone was 
tapered to 1 mg qod, which was accompanied by recurrent 
diplopia, dysphagia, gait instability, and neck ache. Examina­
tion revealed a blood pressure of 144/100 mm Hg, pulse 92 per 
minute, respirations 30 to 45 per minute, and temperature 
35.2 °C. Neurologic examination showed worsening of right 
ptosis, bilateral facial weakness (R >  L), and more severe left 
palatal weakness and ataxia. Her eye movement abnormali­
ties persisted. Arterial blood gases on room air showed a Po2 of 
121 mm Hg, Pco2 of 9 mm Hg, pH of 7.61,0 2 saturation (Sa02) 
of 97%, HC03_ of 9 mEq/1, and base deficit of —7.1 mEq/1. 
Urine pH was 5.0. Gadolinium-enhanced MRI located the 
tumor in the posterior pontine tegmentum, without changes 
in the T2-weighted abnormal signal as compared with the 
prior scan (figure 1, E and F). Polysomnography, EOG, and 
quantitative respiratory evaluation were performed (see be­
low). In the 2 weeks prior to this evaluation, the patient’s only 
medication was dexamethasone 1 mg po qod. After the evalua­
tion, it was observed that single doses of morphine sulfate, 5 
mg IV, produced a reduction in respiratory rate for 18 to 24 
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hours. The patient was restarted on methadone, 5 mg q8h, 
which reduced the respiratory rate to 15 to 20 per minute; 
dexamethasone, 1 mg qod, and PCV chemotherapy were con­
tinued. Repeat MRIs 4 and 11 months later showed reduction 
in enhancement and abnormal T2 signal (figure 1, G and H). 
Dexamethasone was stopped without subsequent tachypnea; 
at follow-up 30 months after tumor diagnosis and 27 months 
following her 1st episode of CNH, she remains neurologically 
stable, without tachypnea, on methadone, 2.5 mg at bedtime.
Methods. Respiratory evaluation. Details of the C02 re­
breathing technique and apparatus (modified after Read) 
have beenpreviouslypublished.5 Briefly, the subject wore nose 
clips and breathed through a tight-fitting mouthpiece at­
tached to a low-resistance circuit and a 7.0 1 neoprene bag, 
which was primed with 100% 0 2 to a volume of 1.0 1 greater 
than vital capacity. End-tidal C02 was measured at the mouth 
with an infrared C02 analyzer (Beckman LB-2). The signal 
from a Fleisch pneumotachograph was electronically inte­
grated to measure ventilation. Occlusion of the airway was 
achieved by a microcomputer-controlled solenoid valve, and 
the occlusion pressure at 100 msec after the onset of inspira­
tion (P0J) was measured by a pressure transducer. Subjecting 
the patient to a C02 challenge to assess brainstem respiratory 
drive presented difficulties that are not normally encountered. 
The usual priming of the rebreathing apparatus (approxi­
mately 7% C02 in 0 2) would present this patient, whose 
normal end-tidal C02 ranged from 8 to 12 mm Hg, with a 
sudden and stressful C02 level. In addition, priming the re­
breathing apparatus with 7% C02 would not allow a gradual 
linear rise in C02 and ventilatory response, which were neces­
sary for a meaningful interpretation of results. Instead, the 
apparatus was primed with 100% 0 2 in an attempt to avoid 
this problem. The patient was informed that these increases 
in C02 and ventilatory drive might prove difficult to tolerate. 
She was, however, a highly motivated patient who tolerated a 
10-mm Hg rise in end-tidal C02 before stopping the test. After 
baseline evaluation, the patient received morphine sulfate, 10 
mg IV, and C02 challenge was performed as above. Thirty 
minutes later, naloxone 0.8 mg was administered, followed by 
another C02 challenge. The same protocol was repeated 48 
hours later, except that naloxone 10 mg was used instead of 0.8 
mg. No opiates were administered between these evaluations.
Polysomnography. The polygraphic sleep study was per­
formed in the patient’s private room on the neurology ward 
according to standard clinical guidelines6 and interpreted by 
one of the authors (C.R.J.), who is certified by the American 
Sleep Disorders Association as an Accredited Clinical Poly- 
somnographer. EEG channels necessary to stage sleep (C3-A2, 
and Oj-A2), 2 channels of horizontal EOG, submental EMG, 
ECG, rib cage and abdominal breathing movements (Res- 
pitrace breathing monitor) were recorded at 10 mm/sec paper 
speed on a 12-channel Nihon-Kohden polygraph machine. 
Sa02 was continuously recorded from a Nellcor model N-200 
pulse oximeter (fast-response mode) on a multichannel, slow- 
speed Linseis strip chart recorder. The patient tolerated a full 
(nose and mouth) face mask with a dead space of approxi­
mately 50 cc without additional dyspnea, perhaps because of 
her large tidal volumes (1,000 cc). Essentially all the exhaled 
tidal volume passed through the wide-bore sampling port of a 
Novametrix model 1260 end-tidal C02 monitor attached to 
the face mask. The monitor was calibrated using 0% and 5% 
C02 gas mixtures. Waking values of end-tidal C02 obtained 
with this method just prior to the sleep study were consis­
tently 12 to 14 mm Hg. A waking arterial Pco2 was 9 mm Hg 
prior to the sleep study, which we considered to reflect a 
comparable degree of hyperventilation for the purposes of this 
study. The Novametrix sampling port has been used routinely
for continuous in-line C02 monitoring of intubated patients 
and does not contribute clinically significant airway resis­
tance. The polygraphic recording was visually scored for sleep 
stages by 30-second epochs according to the criteria of Recht- 
schaffen and Kales.7 The digital readout of the end-tidal C02 
monitor was manually recorded in real time on the appropri­
ate polygraph page. The corresponding simultaneous respira­
tory rate was obtained from the respiratory polygraph 
channels by averaging over 1 minute. The above values were 
plotted on the same time scale as the strip chart recording of 
Sa02 and heart rate to produce a summary sleep graph (hyp- 
nogram).
R esults. R espiratory evaluation. Pulmonary function 
tests, including spirometry and lung volumes, were nor­
mal. Corrected D lc0 (diffusion capacity) was reduced to 
62% of predicted; however, chest radiograph, clinical 
examination, and arterial blood gases showed no evi­
dence of interstitial disease. The C 02 challenges were 
considered successful in that (1) a rapid equilibrium 
between rebreathing circuit and alveolar C 02 was estab­
lished, as demonstrated by the small differences be­
tween inspired and expired C 02 tensions; (2) a linear 
increase occurred in the ventilatory and occlusion pres­
sure response that was parallel to linear increase in the 
end-tidal C 0 2; and (3) the patient’s baseline responses 
to C 02 were well within the range of normal. Morphine, 
10 mg IV, depressed the ventilatory response to C 02 to 
49 to 53% of baseline and the occlusion pressure re­
sponse to 35 to 50% (figure 2). Similar doses (0.21 mg/ 
kg) had previously produced virtually identical depres­
sion of the ventilatory and occlusion pressure responses 
(57% and 47%, respectively) in normal young adults8. 
Naloxone, 0.8 mg IV, produced no significant reversal of 
respiratory morphine-induced depression of the ven­
tilatory and occlusion pressure response to C 02, while 
naloxone, 10 mg, restored these responses to baseline 
(figure 2).
Polysom nography. The polysomnographic testing 
revealed fragm ented sleep, w ith frequent, unex­
plained awakenings, although the patient reported a 
relatively normal night of sleep (figure 3). Slow-wave 
(delta) sleep constituted 12.7% of total sleep time and 
was confined primarily to the first of the night. 
Careful inspection of the entire polygraph showed no 
EEG, EOG, or EMG evidence (either singly or in com­
bination) for rapid eye movement (REM) sleep, and the 
patient reported no dreams. Respiratory monitoring 
showed a rate of 25 to 30 per minute throughout the 
night. The S a02 was also abnormally high (98 to 100%), 
especially for the altitude of the University of Utah 
(1,500 m above sea level, barometric pressure 630 to 
640 mm Hg).  Essentially all apparent 0 2 desaturation 
events shown in figure 3 represented movement ar­
tifacts, correlating with visual observations of inter­
rupted sleep. End-tidal C 0 2 values remained <15 mm 
Hg for almost the entire night, consistent with sus­
tained hyperventilation during all stages of non-rapid 
eye movement (NREM ) sleep. Finally, the poly­
graphic morphology of inspiratory rib cage and ab­
dom inal breathing m ovem ents provided further 
qualitative evidence for increased respiratory drive 
throughout sleep.
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Figure 2. Ventilatory and occlusion pressure response to C02. (A) Changes in the slope of the ventilatory response to C 02 in 
the CNH patient before and after morphine, 10 mg IV, and after antagonism with naloxone, 0.8 mg ( • —•  ) and 10.0 mg 
( O--O ). Data modified from Bailey et al2 for the responses (mean) in 12 healthy young adults, before and after morphine,
0.21 mg/kg, and after antagonism with naloxone, 0.014 mg/kg (  □------ □ ). (B) Changes in the slope of the occlusion pressure
response to C02 in the CNH patien t before and after morphine, 10 mg IV, and after antagonism with naloxone 0.8 mg 
( • — •  ) and 10 mg (  0 —0  )■ Data modified from Bailey et al2 for the responses (mean) in 12 healthy young adults before and 
after morphine, 0.21 mg/kg, and after antagonism with naloxone, 0.014 mg/kg (□ ------ □ ).
D iscussion . By definition, CNH persists despite a nor­
mal or high Po2, a low P co2, and an elevated arterial 
pH.3 Unlike psychogenic tachypnea, CNH persists dur­
ing sleep and must not be due to ingestion of respiratory 
stimulants such as salicylates or cyanide.3 The syn­
drome is rare, with only 10 prior tumor-associated cases 
reported and in only 4 of which the patient has been 
alert.1'3-1015 Except for the 2 patients with hepatic en­
cephalopathy described by Plum,3 all patients have had 
brainstem astrocytomas or CNS lymphomas as associ­
ated conditions.1015 The clinical features of CNH have 
been elaborated upon elsewhere.2-3
The pathophysiologic mechanism involved in the 
production of CNH is unclear. Originally, dysfunction 
of the reticular formation of the midbrain and upper 
pons was thought to be correlated with this syndrome.2 
However, destructive midbrain and pontine lesions in 
animals did not produce CNH.3 9 Plum originally sug­
gested3 that local production of lactic acid by tumor 
cells in the brainstem results in an increase in hydrogen 
ion concentration, which stimulates chemosensitive 
respiratory neurons. This concept is supported by the 
finding of elevated CSF lactate and low CSF pH in CNH 
patients.3,11 However, the absence of CNH in other 
patients with brainstem tumors, in which local medul­
lary lactate concentration would presumably also be 
elevated, suggests that other unknown factors might be 
involved. In addition, CNH is rare in patients with 
meningitis (carcinomatous or infectious), in which CSF 
lactate is commonly elevated. In contrast, Arnold et al16 
have identified relatively normal pH within experimen­
tal gliomas with alkalosis of the surrounding tumor 
microenvironment. It is clear that the role of local 
brainstem pH in the pathogenesis of CNH has yet to be 
defined.
One might assume that the medullary respiratory
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center must be intact for production of this syndrome, 
with disruption of descending inhibitory neurons from 
the pons, mesencephalon or cerebral cortex. Neverthe­
less, many of the described patients have extensive 
infiltration of the medulla as well.3-12'13 Cohn et al11 
described a case in which tumor involved only the right 
brainstem; since rostral brainstem respiratory reg­
ulatory effects are bilaterally represented,9 disinhibi- 
tion was unlikely to be responsible for CNH in their 
patient. Another problem is posed by the case described 
by Bateman et al,14 in which the brainstem below the 
superior colliculus was free of lymphoma, except for 
meningeal metastases. It is possible that the CNH was 
produced by undetermined indirect effects of meningeal 
tumor in these cases without definite brainstem in­
volvement. Our patient had an extensive lesion involv­
ing tegmentum and tectum of the upper medulla and 
dorsal pons. By MRI, the abnormal signal progressed 
into the medulla when CNH initially occurred; how­
ever, it would only be speculative to suggest that the 
medullary extension was responsible for the CNH.
In our patient, morphine sulfate resulted in a rapid 
reduction of the respiratory rate, which was sustained 
with oral methadone. The patient of Rodriquez et al12 
responded transiently to morphine sulfate. Neurons 
containing both mu and delta opiate receptors are pres­
ent in feline brainstem respiratory-related neurons, lo­
cated in the nucleus solitarius, nucleus ambiguus, and 
reticular formation, which exert direct control on cen­
tral transmission of rhythmic signals related to respira­
tion.17 Experimental evidence suggests that opiates 
binding to both mu and delta receptors will decrease 
respiratory rate, rhythmicity, and pattern, as well as 
responsivity to C 02.1819 However, little information is 
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Figure 3. Sleep study summary graph. Summary of 
polysomnographic results showing sleep stages and 
simultaneous respiratory determinations across the night. 
Percent 0 2 saturation was measured with a pulse oximeter. 
Respiratory rate/minute was calculated from the 
continuous recording of breathing movements. End-tidal 
CO2 (mm Hg) is the partial pressure of carbon dioxide 
measured at the mouth. Sleep stages are shown for 
wakefulness (wake), rapid eye movement sleep (REM) and 
stages 1 through 4 non-rapid eye movement sleep (1, 2, 3,
4). Arrow near the beginning of the sleep period indicates 
the time the room lights were turned off. Certain 
oscillations in 0 2 saturation (especially between midnight 
and 1:15 a m ) were actually movement artifacts.
Two features of our patient’s response to opiates and 
the antagonist naloxone are notable. First, morphine 
and methadone produced clinical effects (therapeutic 
relief of dyspnea and tachypnea) that far outlasted their 
predicted duration from the known pharmacokinetics 
of these agents. Second, a dose of naloxone (0.8 mg), 
which usually restores C 02 responsiveness to baseline 
in adults who have received similar doses of morphine,5 
failed to produce reversal of morphine-induced respira­
tory depression in our patient. Supramaximal doses of 
naloxone (10 mg) were necessary to achieve this effect. 
The reason for the prolonged response to morphine and 
the requirement for an extremely high naloxone dose for 
reversal of effect is unclear. One unproven hypothesis is 
that morphine was capable of initiating an alteration of 
the set point of medullary respiratory neuronal drive, 
and once altered, maintenance of the new respiratory 
rate was not farther influenced by conventional doses of 
opiate agonist or antagonist.
The polygraphic sleep study documented the per­
sistence of hyperventilation throughout all stages of 
NREM sleep, thereby eliminating psychogenic hyper­
ventilation as a possibility. The patient’s hyperventila­
tion was presumably driven by medullary inspiratory- 
and expiratory-related neuronal groups near the nu­
cleus retroambiguus and nucleus tractus solitarius,20,21 
which may have been spared from tumor involvement.
On the other hand, sleep stage abnormalities in the 
polysomnogram suggested dysfunction of certain brain­
stem tegmental structures. The most striking finding 
was the total absence of REM sleep. Although it is not 
uncommon during the 1st night’s recording to observe a
missed REM period or prolonged REM latency,22 the 
total absence of REM sleep suggests pontine tegmental 
injury.23 By stimulation and lesion studies, Seigel23 
demonstrated that the lateral rostral pontine reticular 
formation ventral to the locus ceruleus is critical for 
REM sleep in the cat. In our patient, it is possible that 
diffusely infiltrative tumor may have extended from 
this area to the adjacent parapontine reticular forma­
tion (PPRF), with resultant impairment of horizontal 
saccades in both REM sleep and the awake state. The 
authors are well aware of the shortcomings of a single 
night’s polysomnographic recording, and that con­
clusions based on these results have limitations. How­
ever, the association of a medial pontine tegmental 
lesion with absent REM sleep is consistent with the 
report of Autret et al,24 who described reduction in 
REM and NREM sleep with lateral gaze paralysis and 
internuclear ophthalmoplegia in 4 cases of brainstem 
stroke in which the common pathologic lesions were 
localized in the medial pontine tegmentum.
In our patient, the lack of volitional horizontal sac­
cades with compensatory head thrusts is reminiscent of 
congenital ocular motor apraxia. However, since spon­
taneous, random (ie, reflexive) horizontal saccades were 
also absent, the findings do not fit strict criteria for a 
true apraxia.25 Loss of horizontal volitional and reflex­
ive saccades, with preservation of the vestibular ocular 
reflex and vertical saccades, is consistent with dysfunc­
tion of the PPRF. Our patient developed bilateral ab­
ducens palsies with mild internuclear ophthalmoplegia 
and CNH simultaneously; these abnormalities suggest 
dysfunction of areas quite proximal to the PPRF. It is 
unclear why the CNH, but not the ocular motor dys­
function, improved. It is possible that reversible physio­
logic factors (eg, edema, pH, opiate receptor binding) 
were involved in CNH production, whereas permanent 
structural alterations due to tumor affected ocular 
motor function.
In summary, the clinical findings in our patient im­
plicate a medial tegmental pontine lesion, possibly af­
fecting the PPRF bilaterally. These data would be 
consistent with a model of CNH that is based on the 
disinhibition of pontine inhibitory influence on medul­
lary respiratory neurons, but by no means is this mecha­
nism clearly responsible in our patient. The sustained 
response of this patient’s hyperventilation to opiates 
warrants consideration of this treatment in other pa­
tients with CNH.
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